7 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Mycobacterium tuberculosis ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
IDSA - Prophylaxis ... Mycobacterium tuberculosis ... Infections #OIs #HIVAIDS ... #IDSA #management ... #pharmacology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... ) Pathophysiology ... Latent: Asymptomatic ... (Anorexia) • Night ... TB #Diagnosis #Management
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... ) Pathophysiology ... Latent: Asymptomatic ... (Anorexia) • Night ... TB #Diagnosis #Management
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Initiating Primary Prophylaxis ... a hyperendemic rate ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
1 dose (BII) Late-Latent ... 28 days (BIII) Late-Stage ... consultation to guide management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... for active or latent ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology